Patents Assigned to The Wistar Institute
  • Patent number: 11945851
    Abstract: Disclosed herein are compositions and methods for treating and/or preventing cancer in mammals, and in particular, vaccines that treat and provide protection against tumor growth.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: April 2, 2024
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: David Weiner, Elizabeth Duperret
  • Patent number: 11925685
    Abstract: Disclosed herein is a composition comprising a recombinant nucleic acid sequence that encodes an antibody to a Zika viral antigen, and functional fragments thereof. The invention also relates to a composition comprising the combination of a first composition that elicits an immune response in a mammal against zika virus and a second composition comprising a recombinant nucleic acid sequence encoding an antibody, a fragment thereof, a variant thereof, or a combination thereof. In some instances, the nucleic acid molecule comprises a nucleotide sequence encoding an anti-ZIKV-Envelope (anti-ZIKV E) Protein antibody.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: March 12, 2024
    Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc., The Wistar Institute of Anatomy and Biology
    Inventors: David Weiner, Karuppiah Muthumani, Jian Yan
  • Patent number: 11912659
    Abstract: The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: February 27, 2024
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Troy E. Messick, Garry R. Smith, Allen B. Reitz, Paul M. Lieberman, Mark E. McDonnell, Yan Zhang, Marianne Carlsen, Shuai Chen
  • Patent number: 11896654
    Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets an immune checkpoint molecule. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: February 13, 2024
    Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals
    Inventors: David B. Weiner, Kar Muthumani, Niranjan Sardesai
  • Patent number: 11883484
    Abstract: The present invention relates to compositions comprising two or more DNA plasmids encoding consensus and transmitted founder HIV envelope glycoproteins which expressed and induce a potent immune response.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: January 30, 2024
    Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology
    Inventors: David Weiner, Megan Wise
  • Publication number: 20240009223
    Abstract: The present disclosure provide for methods of using 6-thio-2?-deoxyguanosine (6-thio-dG) to treat telomerase-positive cancers that exhibit (a) one or more TERT promoter mutations, and/or (b) enriched telomere transcriptional signature(s). In particular, melanomas, including those who are not sensitive or have become resistant to immune checkpoint inhibition and/or MAPKi therapy are targets for this therapy.
    Type: Application
    Filed: June 5, 2023
    Publication date: January 11, 2024
    Applicants: The Board of Regents of The University of Texas System, The Wistar Institute of Anatomy and Biology
    Inventors: Jerry W. SHAY, Gao ZHANG
  • Patent number: 11865166
    Abstract: Provided herein is an immunogenic composition comprising a synthetic consensus antigen to Follicle Stimulating Hormone Receptor (FSHR) protein which is abundant in many ovarian cancer sub-types. Also disclosed herein is a method of treating a tumor associated pathology in a subject in need thereof, by administering the immunogenic composition to the subject.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: January 9, 2024
    Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc., The Wistar Institute of Anatomy and Biology
    Inventors: David Weiner, Alfredo Perales Puchalt, Jian Yan, Anna Maria Slager
  • Patent number: 11850282
    Abstract: Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.
    Type: Grant
    Filed: February 24, 2022
    Date of Patent: December 26, 2023
    Assignees: Virion Therapeutics, LLC, The Wistar Institute
    Inventors: Hildegund C J Ertl, Colin Stephen Magowan
  • Patent number: 11851477
    Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an anti-influenza-hemagglutinin synthetic antibody. The disclosure also provides a method of preventing and/or treating influenza in a subject using said composition and method of generation.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: December 26, 2023
    Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals, Inc.
    Inventors: David B. Weiner, Ami Patel, Jian Yan, Sarah Elliott
  • Patent number: 11845787
    Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to an HIV antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an HIV infection in a subject using said composition and method of generation.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: December 19, 2023
    Assignees: The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals, Inc.
    Inventors: David Weiner, Megan Wise
  • Patent number: 11833137
    Abstract: The present invention includes substituted chromenones that are useful to inhibit the IRE1/XBP-1 pathway. In certain embodiments, the compounds of the invention inhibit IRE1's RNase activity. In other embodiments, the compounds of the invention are useful to treat or prevent a cancer that involve activation of the ER stress response. The invention also relates, in certain aspects, to the discovery that secretory IgM (sIgM) can orchestrate an immunosuppressive microenvironment by recruiting myeloid-derived suppressor cells (MDSCs) into different tumor models, such as but not limited to solid tumors (such as but not limited to lung cancer) and tumors that have high levels of secreted IgM. In certain embodiments, sIgM produced by B cells or CLL cells can contribute to the accumulation of MDSCs in a tumor. In other embodiments, inhibition of the IRE1/XBP-1 pathway can ablate, minimize, or reduce MDSC levels in a tumor.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: December 5, 2023
    Assignees: The Wistar Institute, University of South Florida
    Inventors: Chih-Chi Andrew Hu, Juan R. Del Valle
  • Publication number: 20230285549
    Abstract: Disclosed are compositions comprising an expressible nucleic acid sequence comprising a first nucleic acid sequence comprising a sequence that encodes an adjuvant polypeptide or a pharmaceutically acceptable salt thereof and a second nucleic acid sequence comprising a sequence that encodes an antigen from a virus or from a cancer. In some embodiments, the expressible nucleic acid sequence further comprises a nucleic acid sequence encoding at least one viral antigen or a pharmaceutically acceptable salt thereof. In some embodiments, the expressible nucleic acid sequence further comprises at least one nucleic acid sequence encoding a linker.
    Type: Application
    Filed: June 30, 2021
    Publication date: September 14, 2023
    Applicant: THE WISTAR INSTITUTE OF ANATOMY & BIOLOGY
    Inventors: Ziyang XU, Daniel W. KULP, David B. WEINER
  • Patent number: 11718685
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention relates to targeting the stromal cell population in a tumor microenvironment. For example, in one embodiment, the invention provides a composition that is targeted to fibroblast activation protein (FAP). The invention includes a chimeric antigen receptor (CAR) which comprises an anti-FAP domain, a transmembrane domain, and a CD3zeta signaling domain.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: August 8, 2023
    Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology
    Inventors: Carl H. June, Ellen Pure, Liang-Chuan Wang, Steven Albelda, John Scholler
  • Patent number: 11702675
    Abstract: This disclosure provides replication-incompetent adenoviral vectors useful in vaccine development and gene therapy. The disclosed vectors comprise a selective deletion of E3 and are particularly useful for preparation of vaccines development and for gene therapy using toxic transgene products that result in vector instability that occurs when the entire E3 domain is deleted.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: July 18, 2023
    Assignee: The Wistar Institute
    Inventors: Hildegund C. J. Ertl, Xiang Yang Zhou
  • Publication number: 20230181543
    Abstract: The present disclosure is directed to the use of IRE-1 and/or XBP-1 inhibitors to treat cancers having mutations in ARID 1 A over overexpressing CARM1.
    Type: Application
    Filed: February 26, 2021
    Publication date: June 15, 2023
    Applicant: The Wistar Institute of Anatomy and Biology
    Inventors: Rugang ZHANG, Joseph ZUNDELL, Jianhuang LIN
  • Patent number: 11660335
    Abstract: Disclosed herein are nucleic acid molecules encoding a SARS-CoV-2 spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection in a subject.
    Type: Grant
    Filed: February 25, 2021
    Date of Patent: May 30, 2023
    Assignees: Inovio Pharmaceuticals, Inc., The Wistar Institute of Anatomy and Biology
    Inventors: Jian Yan, Kate Broderick, David Weiner, Kar Muthumani, Ami Patel
  • Patent number: 11661632
    Abstract: Methods and compositions are provided for diagnosing lung cancer in a mammalian subject by use of 10 or more selected genes, e.g., a gene expression profile, from the blood of the subject which is characteristic of disease. The gene expression profile includes 10 or more genes of Table I or Table II herein.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: May 30, 2023
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Michael Showe, Louise C. Showe, Andrei V. Kossenkov
  • Patent number: 11648303
    Abstract: An aspect of the present invention is related to nucleic acid constructs capable of expressing a Zika antigen that elicits an immune response in a mammal against Zika virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a Zika virus, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a Zika antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal that is cross reactive against all Zika strains.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: May 16, 2023
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
    Inventors: David Weiner, Kar Muthumani
  • Patent number: 11596678
    Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Marburgvirus filovirus glycoprotein immunogens. Immunomodulatory methods and methods of inducing an immune response against Marburgvirus are disclosed. Method of preventing infection by Marburgvirus and methods of treating individuals infected with Marburgvirus are disclosed. Consensus Marburgvirus filovirus glycoprotein immunogens are disclosed.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: March 7, 2023
    Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomv and Biologv
    Inventors: David Weiner, Ami Patel, Sarah Elliott
  • Patent number: 11524065
    Abstract: Nucleic acid molecules and compositions comprising one or more nucleotide sequences that encode a consensus Merkel Cell Polyomavirus (MCV) T antigen. Immunomodulatory methods and methods of inducing an immune response against MCV are disclosed. Method of treating infection by MCV and methods of treating or preventing Merkel Cell Carcinoma associated with MCV are disclosed. Modified consensus MCV T antigens are disclosed.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: December 13, 2022
    Assignee: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
    Inventors: David B. Weiner, Elizabeth Duperret